Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

KRYSTEXXA: Our Commercial Strategy Has Accelerated Volume Growth Increasing Our Peak U.S. Annual Net Sales Expectations to >$1B" (1) KRYSTEXXA Net Sales Driven by Vial Growth Growth Drivers >$1B(1) Growth in New and 1 Existing Accounts Accelerating 2 Nephrology Growth 32% 65% 72% $342M $259M $91M $157M 3 2016 2017 2018 2019 Peak U.S. Annual Net Sales (1) Horizon estimate. HORIZON Growth in use of KRYSTEXXA plus Methotrexate 25

View entire presentation